A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®
Adult
Anti-Inflammatory Agents, Non-Steroidal
/ therapeutic use
Budesonide
/ administration & dosage
Cohort Studies
Colitis, Ulcerative
/ drug therapy
Dosage Forms
Drug Therapy, Combination
Female
Glucocorticoids
/ administration & dosage
Humans
Male
Mesalamine
/ therapeutic use
Middle Aged
Prospective Studies
Severity of Illness Index
Treatment Outcome
5-ASA
MMX
Ulcerative colitis
budesonide
inflammatory bowel disease
mesalamine
Journal
United European gastroenterology journal
ISSN: 2050-6406
Titre abrégé: United European Gastroenterol J
Pays: England
ID NLM: 101606807
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
17
05
2019
accepted:
20
06
2019
entrez:
9
11
2019
pubmed:
9
11
2019
medline:
9
11
2019
Statut:
ppublish
Résumé
Cortiment® This was a multicentre observational prospective cohort study conducted in Europe and Canada. Effectiveness, safety, and tolerability of Cortiment® Data from 326 patients with mild-to-moderate UC were analysed for the primary endpoint. Clinical benefit was achieved in 60.1% (196/326) of patients at the end of Cortiment® This was the first time that a large cohort study was conducted with Cortiment®
Sections du résumé
Background
Cortiment®
Methods
This was a multicentre observational prospective cohort study conducted in Europe and Canada. Effectiveness, safety, and tolerability of Cortiment®
Results
Data from 326 patients with mild-to-moderate UC were analysed for the primary endpoint. Clinical benefit was achieved in 60.1% (196/326) of patients at the end of Cortiment®
Conclusions
This was the first time that a large cohort study was conducted with Cortiment®
Identifiants
pubmed: 31700630
doi: 10.1177/2050640619864848
pii: 10.1177_2050640619864848
pmc: PMC6826527
doi:
Substances chimiques
Anti-Inflammatory Agents, Non-Steroidal
0
Dosage Forms
0
Glucocorticoids
0
Mesalamine
4Q81I59GXC
Budesonide
51333-22-3
Types de publication
Journal Article
Multicenter Study
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1171-1182Informations de copyright
© Author(s) 2019.
Références
J Crohns Colitis. 2017 Jan;11(1):3-25
pubmed: 27660341
Am J Gastroenterol. 2015 Sep;110(9):1324-38
pubmed: 26303131
Gastroenterology. 2012 Nov;143(5):1218-1226.e2
pubmed: 22892337
J Crohns Colitis. 2017 Jul 1;11(7):769-784
pubmed: 28513805
N Engl J Med. 2011 Nov 3;365(18):1713-25
pubmed: 22047562
Drugs. 2007;67(17):2635-42
pubmed: 18034594
Am J Gastroenterol. 1996 Aug;91(8):1571-8
pubmed: 8759664
J Crohns Colitis. 2017 Jun 1;11(6):649-670
pubmed: 28158501
Am J Gastroenterol. 2001 Oct;96(10):2921-8
pubmed: 11693327
Eur Orthop Traumatol. 2012 Jun;3(2):101-105
pubmed: 22798966
J Int Med Res. 2013 Apr;41(2):386-94
pubmed: 23569029
Br J Clin Pharmacol. 2006 Jan;61(1):31-8
pubmed: 16390349
J Crohns Colitis. 2010 Jun;4(2):153-60
pubmed: 21122499
Scand J Gastroenterol. 2009;44(4):431-40
pubmed: 19101844
Qual Life Res. 2004 Mar;13(2):311-20
pubmed: 15085903
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
Clin Gastroenterol Hepatol. 2018 May;16(5):637-647.e13
pubmed: 28843356
Adv Ther. 2007 Jul-Aug;24(4):826-40
pubmed: 17901032
J Crohns Colitis. 2015 Sep;9(9):738-46
pubmed: 26094251
Am J Gastroenterol. 2000 Jan;95(1):145-51
pubmed: 10638574
Gut. 2014 Mar;63(3):433-41
pubmed: 23436336
Inflamm Bowel Dis. 2005 May;11(5):421-7
pubmed: 15867580
Br J Clin Pharmacol. 2018 Feb;84(2):239-251
pubmed: 29057539